Comparable stake leader
ARMISTICE CAPITAL, LLC
SEC ownership of Arcadia Biosciences, Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001469443.
Disclosed value leader
ARMISTICE CAPITAL, LLC
Comparable rows
20/32
Latest evidence
30 Jun 2026
- Public ticker
- RKDA on Nasdaq
- Parsed ownership sources
-
13D/G, 13F, and 3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
ARMISTICE CAPITAL, LLC
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
20 of 32
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
ARMISTICE CAPITAL, LLC
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
30 Jun 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001469443
- Issuer location
- Dallas, TX
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Arcadia Biosciences, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
ARMISTICE CAPITAL, LLC
Disclosed value leader
ARMISTICE CAPITAL, LLC
Comparable rows
20/32
Latest evidence
30 Jun 2026
13D/G
13F
3/4/5
Lead comparable stake: 10%
12 rows are not safely comparable across share classes.
13D/G row: ARMISTICE CAPITAL, LLC
Showing 1-8 of 32 holder rows.
Quick read
ARMISTICE CAPITAL, LLC leads the comparable SEC ownership view at 10%.
20 of 32 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens ARMISTICE CAPITAL, LLC's linked filing trail.
Comparable ownership
Top 5
ARMISTICE CAPITAL, LLC
10%
SABBY MANAGEMENT, LLC
4.9%
HRT FINANCIAL LP
3.3%
CITADEL ADVISORS LLC
0.89%
Virtu Financial LLC
0.81%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 32 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| ARMISTICE CAPITAL, LLC |
13D/G
|
10%
|
$181,586
267,392 shares
|
$0 | 30 Jun 2026 |
| SABBY MANAGEMENT, LLC |
13D/G
|
4.9%
|
$17,028
68,111 shares
|
$0 | 31 Dec 2024 |
| HRT FINANCIAL LP |
13F
Company
|
3.3%
|
$60,000
88,386 shares
|
— | 30 Jun 2026 |
| CITADEL ADVISORS LLC |
13F
Company
|
0.89%
|
$16,120
23,738 shares
|
— | 30 Jun 2026 |
| Virtu Financial LLC |
13F
Company
|
0.81%
|
$15,000
21,786 shares
|
— | 30 Jun 2026 |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
Company
|
0.6%
|
$10,957
16,135 shares
|
— | 30 Jun 2026 |
| XTX Topco Ltd |
13F
Company
|
0.58%
|
$10,509
15,475 shares
|
— | 30 Jun 2026 |
| StoneX Group Inc. |
13F
Company
|
0.51%
|
$11,259
13,682 shares
|
— | 30 Jun 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Insider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 12 Sep 2025.
Buys
$0
Insiders: 0
Sells
$0
Insiders: 0
Net
$0
Shares: 0
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-12 of 12 reporting-owner rows connected to Arcadia Biosciences, Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
12
Largest Forms 3/4/5 holder
Stanley Jacot Jr.
Net 12M change
$0
Latest report
09 May 2025
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Stanley Jacot Jr. | Chief Executive Officer | $18,350 | Mixed | 30 May 2023 | ||
| Thomas J. Schaefer | Chief Executive Officer | $7,019 | Filing P/S | 09 May 2025 | ||
| Mark Kawakami | Chief Financial Officer | $6,676 | Filing P/S | 09 May 2025 | ||
| Albert D. Bolles | Director | Mixed | 19 Aug 2024 | |||
| Gregory D. Waller | Director | Mixed | 19 Aug 2024 | |||
| Laura Pitlik | Chief Marketing Officer | Mixed | 04 Apr 2023 | |||
| Pamela Haley | Chief Financial Officer | Mixed | 16 Aug 2022 | |||
| Amy Yoder | Director | Mixed | 19 Aug 2024 | |||
| Lilian Shackelford Murray | Director | Mixed | 19 Aug 2024 | |||
| Chris Cuvelier | Chief Growth Officer | Mixed | 17 May 2021 | |||
| Kevin Comcowich | Director | Mixed | 19 Aug 2024 | |||
| Deborah D. Carosella | Director | Mixed | 19 Aug 2024 |
Recent insider transactions for Arcadia Biosciences, Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| No insider transactions were found in the last 12 months for this issuer. | ||||||||||
* marks a reported price that did not pass the local price check.